CDKN2B Antikörper (Cy7)
Kurzübersicht für CDKN2B Antikörper (Cy7) (ABIN706172)
Target
Alle CDKN2B Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Spezifität
- Excitation / Emission Wavelengths: 743nm/767nm
-
Kreuzreaktivität
- Ratte (Rattus), Huhn, Hund, Rind (Kuh)
-
Aufreinigung
- purified by Protein A
-
Immunogen
- KLH conjugated synthetic peptide derived from human CDKN2B
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
IF(IHC-P)(1:100-500)
Optimal working dilution should be determined by the investigator. -
Kommentare
-
Excitation / Emission wavelength: 743nm / 767nm
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 µg/µL
-
Buffer
- Aqueous buffered solution containing 100 µg/mL BSA, 50 % glycerol and 0.09 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- Store at 4 °C for 12 months
-
Haltbarkeit
- 12 months
-
-
- CDKN2B (Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) (CDKN2B))
-
Andere Bezeichnung
- CDKN2B
-
Hintergrund
- P15 INK4b / MTS 2 (Mitotic Inhibitor / Suppressor Protein) is a specific inhibitor of cdk 4 / cdk 6 and is periodically expressed during the cell cycle. Reportedly, p15 INK4b expression is induced approximately 30 fold in human keratinocytes by treatment with TGF beta, suggesting that p15 INK4b may act as an effector of TGF beta mediated cell cycle arrest. p15 INK4b is mapped to chromosome 9p21, a region of frequent loss in a wide variety of cancers.
-
Molekulargewicht
- 15kDa
-
Gen-ID
- 1030
-
Pathways
- Zellzyklus, Mitotic G1-G1/S Phases
Target
-